Innovating antibodies, improving lives

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.


Q1 260x173First Quarter 2019 Financial Results

Genmab will publish its First Quarter 2019 financial results after market close on May 8. An investor conference call to discuss the results will be held at 6:00 PM CDT / 12:00 PM EDT on May 8. To join the call by phone, dial one of the following numbers and provide confirmation code 8692103: +45 32728042 in Denmark, +44 2071 928000 in the UK and +1 631 510 7495 in the US. Click here to listen to the webcast. 


Genmab 20 Years LogoCelebrating 20 Years

Genmab celebrates its 20th anniversary this year. We asked employees and external stakeholders for their perspectives on Genmab. Click here to watch the video and find out what they said.



join our team_260x173Career Opportunities at Genmab

Genmab is seeking new employees to join our team. Visit our Careers webpages to explore current vacancies, learn about our culture and meet some of our team members. Click here to visit Genmab's page on LinkedIn.